The company, which focuses on treatments for chronic kidney disease, saw its shares close at HK$46.0, marking a 103.54% increase from the initial offer price of HK$22.60. This performance underscores investor appetite for Alebund’s specialized renal pipeline, which includes candidates for hyperphosphatemia and IgA nephropathy. The public offering saw overwhelming demand, with the Hong Kong tranche oversubscribed by approximately 963.56 times.

Alebund’s market entry was backed by a consortium of major institutional investors, including GIC, Tencent, and Cormorant, who collectively accounted for nearly half of the shares offered. CEO Dr. Gavin Xia described the listing as a pivotal moment for the company, which is currently transitioning from a research-focused entity to a commercial biopharma firm. With the successful debut, Alebund intends to accelerate clinical trials for its core assets, including the lead candidate AP301, which is nearing a New Drug Application submission in China.